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Background: Clinical and functional studies consider major depression (MD) and vascular depression (VD) as
different neurobiological processes. Hypoexcitability of the left frontal cortex to transcranial magnetic stimulation
(TMS) is frequently reported in MD, whereas little is known about the effects of TMS in VD. Thus, we aimed to
assess and compare motor cortex excitability in patients with VD and MD.
Methods: Eleven VD patients, 11 recurrent drug-resistant MD patients, and 11 healthy controls underwent clinical,
neuropsychological and neuroimaging evaluations in addition to bilateral resting motor threshold, cortical silent
period, and paired-pulse TMS curves of intracortical excitability. All patients continued on psychotropic drugs, which
were unchanged throughout the study.
Results: Scores on one of the tests evaluating frontal lobe abilities (Stroop Color-Word interference test) were worse
in patients compared with controls. The resting motor threshold in patients with MD was significantly higher in the
left hemisphere compared with the right (p < 0.05), and compared with the VD patients and controls. The cortical silent
period was bilaterally prolonged in MD patients compared with VD patients and controls, with a statistically significant
difference in the left hemisphere (p < 0.01). No differences were observed in the paired-pulse curves between patients
and controls.
Conclusions: This study showed distinctive patterns of motor cortex excitability between late-onset depression with
subcortical vascular disease and early-onset recurrent drug resistant MD. The data provide a TMS model of the
different processes underlying VD and MD. Additionally, our results support the “Vascular depression hypothesis”
at the neurophysiological level, and confirm the inter-hemispheric asymmetry to TMS in patients with MD. We
were unable to support previous findings of impaired intracortical inhibitory mechanisms to TMS in patients with
MD, although a drug-induced effect on our results cannot be excluded. This study may aid the understanding of
the pathogenetic differences underlying the clinical spectrum of depressive disorders.
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Recently, the finding that patients with late-onset depres-
sion had higher rates of brain magnetic resonance imaging
(MRI) changes compared with patients with early onset
major depression (MD), has led to the hypothesis that
mood disorders in the elderly may be related to neuro-
biological abnormalities, such as cerebrovascular disease
[1]. In 1997, Alexopoulos and co-workers [2] introduced
the concept of “vascular depression” (VD) as a subtype
of geriatric mood disorder characterised by a late age at
onset or change in the course of early onset depressive
symptoms, persistent symptoms, association with vascu-
lar disease or vascular risk factors and diffuse or multi-
focal cerebrovascular lesions. The “vascular depression
hypothesis”, presenting clinically as a depression-executive
dysfunction syndrome of late-life, states that disruption
of fronto-striatal circuits by vascular lesions predisposes,
precipitates, or perpetuates late-life depressive syndromes
[3]. Indeed, numerous neuroimaging and neuropatho-
logical studies reported increased prevalence and sever-
ity of white matter lesions (WMLs) of vascular origin in
individuals with elderly depression, especially in those
with late-onset illness [4-6].
Nevertheless, depression in the elderly might also result
from a recurrent form of MD with an early onset. How-
ever, compared with patients with recurrent MD, elderly
patients with VD often exhibit a clinical presentation
characterized by psychomotor retardation, lack of inter-
est, limited depressive ideation and insight, and prominent
disability [7,8]. Moreover, patients with late-onset MD
disorder showed specific deficits in attention and execu-
tive function [9,10], whereas patients with recurrent MD
exhibited deficits in episodic memory [11,12]. These neuro-
psychological differences are thought to be associated with
prominent fronto-striatal dysfunction in late-onset MD,
and with a reduction in hippocampal volume in recur-
rent geriatric MD. The rates of anhedonia and comorbid
cardiovascular illness were higher in patients with late-
onset MD [11].
Despite a body of literature on clinical, psychopatho-
logical, and neuroradiological features of both VD and
MD, studies comparing their neurophysiological profiles
are lacking. Previous electroencephalography studies in
MD patients demonstrated decreased neural activity in
the left frontal regions, as shown by an increased alpha
power band [13,14]. Recently, changes in transcranial mag-
netic stimulation (TMS) related-measures of cortical excit-
ability have been shown to be associated with depression.
Specifically, most, but not all, TMS studies in patients with
MD found reduced activation of both excitatory and inhibi-
tory circuits in the left hemisphere [15-19]. Moreover, some
functional neuroimaging studies have shown hypometa-
bolism and hypoperfusion of the left dorsolateral pre-
frontal cortex (DLPFC) in patients with MD [16,17].However, the applicability of the findings obtained with
TMS on the primary motor cortex (M1) and those ob-
tained with other techniques on the DLPFC requires
further investigation.
TMS is a safe and non-invasive neurophysiological in-
vestigation technique used to evaluate the cortico-spinal
tract, cortical motor areas [20], map motor and cognitive
functions, study neural networks, and modulate brain
function with a potential therapeutic aim [21-23]. The
development of specific stimulation protocols, such as
the cortical silent period (CSP) and paired-pulse para-
digms, as well as the emerging concept that motor cortical
output is influenced by non-primary motor areas, includ-
ing the ventral and dorsal premotor cortex, supplementary
motor area, and cingulate cortex [24], has allowed the use
of TMS to explore inhibitory and excitatory interactions
within motor cortical regions in several neuropsychiatric
disorders [25,26]. A single TMS pulse applied over the M1
through the scalp elicits a motor evoked potential (MEP)
in the contralateral target muscles [27,28]. The resting
motor threshold (rMT) is believed to reflect membrane
excitability of cortico-spinal motor neurons, which is
mainly dependent on ion channel conductivity and on
excitatory interneurons that project to these neurons [20].
The CSP refers to a suppression of electromyographic
activity during a voluntary contraction of the target muscle
and depends, at least in part, on inhibitory mechanisms
at the level of the motor cortex, probably mediated by
gamma-aminobutyric acid (GABA)-b receptors [29]. The
paired-pulse TMS couples a suprathreshold magnetic
stimulus with a preceding subthreshold stimulus, and
the response to the paired stimuli may be increased (facilita-
tion) or decreased (inhibition) depending on the interstimu-
lus interval (ISI): at short ISIs (1–4 ms) the conditioning
stimulus determines the intracortical inhibition (ICI)
with respect to the test stimulus, whereas at longer ISIs
(>5 ms) the effect is intracortical facilitation (ICF). ICI
and ICF interactions are likley related to the balance of
GABAergic, dopaminergic, and glutamatergic transmissions
[29]. In a single study evaluating inhibitory/facilitatory
intracortical circuit changes, Bella et al. [30] did not find
significant differences between patients with VD and pa-
tients with subcortical vascular disease (SVD), suggest-
ing that VD with or without depression might result in
a similar neurophysiological profile of cortical excitabil-
ity, probably as a consequence of cerebral small vessel
disease.
In this study, we aimed to assess and compare single
and paired-pulse TMS measures of cortical excitability in
patients with VD versus MD and between hemispheres.
We hypothesised that VD patients would show dis-
tinctive neurophysiological changes compared with MD,
consistent with the involvement of different neurobio-
logical substrates.
Table 1 Pharmacological treatment of MD patients
Subject Medication (daily dosage in mg)
1 Paroxetine (20), Nortriptyline (50), Quetiapine (200), Zolpidem (10)
2 Paroxetine (20), Nortriptyline (50), Quetiapine (200), Zolpidem (10)
3 Sertraline (50), Nortriptyline (50), Quetiapine (200)
4 Sertraline (50), Nortriptyline (50), Quetiapine (200), Zolpidem (10)
5 Sertraline (50), Nortriptyline (50), Olanzapine (7.5)
6 Paroxetine (20), Nortriptyline (50), Olanzapine (7.5), Zolpidem (10)
7 Venlafaxine (75), Nortriptyline (50), Quetiapine (200), Zolpidem (10)
8 Venlafaxine (75), Nortriptyline (50), Quetiapine (200)
9 Venlafaxine (75), Nortriptyline (50), Olanzapine (7.5), Zolpidem (10)
10 Venlafaxine (75), Nortriptyline (50), Olanzapine (7.5), Zolpidem (10)
11 Venlafaxine (75), Nortriptyline (50), Olanzapine (7.5)
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Participants
A sample of 11 patients with VD (6 males and 5 females;
mean age, 67.72 ± 3.29 years; mean education, 7.91 ±
5.75 years), 11 drug-resistant recurrent patients with MD
without SVD at MRI (5 males and 6 females; mean age,
57.18 ± 7.12; mean education, 12.18 ± 5.98) and 11 age-
matched controls (6 males and 5 females; mean age,
67.36 ± 3.75 years; mean education, 9.64 ± 5.08) were
consecutively recruited from the Cerebrovascular Disease
Center and from the Department of Psychiatry of the
University of Catania (Italy).
VD was defined according to the proposed clinical and
neuroradiological diagnostic criteria as follows: evidence
of vascular risk factors; depression onset after the age
of 65 or change in course of depression after vascular
disease in people with early-onset depression; presence
of some of the following features: cognitive impairment
(consisting of, but not limited to, disturbance of executive
functions), psychomotor retardation, limited depressive
ideation, poor insight, disability, absence of family his-
tory of mood disorders, and presence of cerebrovascular
disease on neuroimaging [2,31]. VD patients fulfilled the
brain MRI criteria for SVD [32], including extending
periventricular and deep WMLs or multiple lacunes in
deep grey matter, and at least moderate WMLs. VD
patients had a primary diagnosis of a current major
depressive episode as assessed by the Structured Clinical
Interview for DSM-IV-TR Axis I Disorders (SCID-I). They
were treated for their vascular risk factors with anti-
platelet or anticoagulant medications (aspirin, clopidogrel,
warfarin), anti-hypertensive drugs (angiotensin-converting
enzyme inhibitors, angiotensin II receptor antagonist, di-
uretics, dihydropyridine calcium channel blockers), choles-
terol lowering medications (statins), and oral antidiabetic
drugs or insulin. No patients had focal motor deficits, but a
slight reflex asymmetry was present in three patients. Mean
age at depression onset in the VD patients was 62.27 ±
5.04 years. No patients were on antidepressant treatment
or other psychotropic medicaments.
Drug-resistant MD patients met the DSM-IV-TR clinical
diagnostic criteria for recurrent MD as assessed by the
SCID-I, and showed a poor response in the course of
the current depressive episode (mean duration, 4.33 ±
2.50 months). We defined treatment resistance as drug-
resistance to three adequate courses of antidepressants
from at least two different classes during the current
major depressive episode [33,34].
As shown in Table 1, the pharmacological regimen at
the time of the study was: Selective Serotonin Reuptake
Inhibitors, Tricyclic Antidepressant, Atypical Antipsychotic
Drugs; Serotonin Noradrenaline Reuptake Inhibitors, Tri-
cyclic Antidepressant, Atypical Antipsychotic Drugs. Seven
MD patients were on zolpidem. The pharmacotherapywas unchanged throughout the course of the study. Mean
age at depression onset in MD patients was 27.82 ±
7.32 years and, including the current episode, 6 patients
experienced four major depressive episodes, whereas
the remaining 5 patients were diagnosed with five or
more episodes.
All patients were right-handed, with no history of brain
trauma or seizures, and their general and neurological
examination was unremarkable. Exclusion criteria were
as follows: any non-mood psychotic disorder, chronic
medical illness, endocrinopathies other than diabetes asso-
ciated with depression or affecting cognitive functions
(such as thyroid diseases), alcohol or drug abuse, use
of drugs causing depressive symptoms (i.e. steroids,
beta-blockers, clonidine), Mini Mental State Examination
(MMSE) score <24, cases with cortical and/or cortico-
subcortical non-lacunar territorial infarcts, borderzone
infarcts, haemorrhages, signs of normal pressure hydro-
cephalus and specific causes of WMLs, and any condi-
tion precluding MRI or TMS execution. This study was
approved by the local ethics committee based at the
“Policlinico-Vittorio Emanuele” University Hospital of
Catania (Italy), and all patients provided written informed
consent.
Assessment
All participants underwent a neuropsychological battery
including the MMSE as a screening test for overall cogni-
tive impairment, Clinical Dementia Rating Scale for the
global cognitive and functional status, Frontal Assessment
Battery and the Stroop Color-Word Test interference
(normative values were collected from an Italian popu-
lation sample, Stroop T score, ≤36.92 s; Stroop E errors,
≤4.24) [35] for the evaluation of different frontal lobe abil-
ities, and the 17-item Hamilton Rating Scale for Depres-
sion (HRSD-17) for the rating of depressive symptoms.
Functional status was evaluated by basic and instrumen-
tal activities of daily living (Activity of Daily Living;
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of the control subjects was evaluated by general and
neurological examinations; their mental state, assessed
by means of the SCID-I, was unremarkable. All patients
and controls underwent brain MRI scans, acquired using
a 1.5 T General Electric system, before inclusion into
the TMS study. The protocol included T1-, T2-, proton
density-weighted and fluid-attenuated inversion recovery
scans; slice thickness was 5 mm with a 0.5 mm slice gap.
In the VD group, the severity of deep WMLs was graded
according to the visual scale of Fazekas: 0 = absence; 1 =
punctuate foci; 2 = beginning confluence of foci; 3 = large
confluent areas [36].
Transcranial magnetic stimulation
MEPs of the right and left first dorsal interosseous (FDI)
muscles as well as single-pulse TMS measures of cortical
excitability were elicited using a Magstim 200 stimulator
(The Magstim Company, Whitland, Dyfed, UK) connected
to a 70 mm figure-of-eight coil. The coil was applied with
the handle pointing backwards and laterally, at an angle
of 45° to the sagittal plane, on the optimum site of
stimulation that consistently yielded the largest MEP
(“hot spot”). Electromyographic activity was recorded
from silver/silverchloride surface active electrodes placed
over the motor point of the target muscle, with the refer-
ence electrode placed distally at the metacarpophalangeal
joint of the index finger. Motor responses were amplified
and filtered (bandwidth 3–3000 Hz) with gains of 100 μV
and 5 mV/div.
The rMT was defined, according to the IFCN Commit-
tee recommendation [37], as the lowest stimulus intensity
able to elicit MEPs of an amplitude >50 μV in at least 5
out of 10 trials, with the muscle at rest. The CSP was de-
termined with an approximately 50% of maximum tonic
voluntary contraction of the FDI muscles, induced by
single TMS pulses delivered at 130% of rMT. The mean
CSP duration of five rectified trials was calculated. Cen-
tral motor conduction time (CMCT) was calculated by
subtracting the conduction time in peripheral nerves,
estimated by conventional F-wave techniques, from MEP
latency obtained during moderate active muscle contrac-
tion (10–20% of maximum background force), at a stimu-
lus intensity set at 130% of the rMT [37]. M and F waves
were elicited by applying supramaximal electrical stimula-
tion (constant current square-wave pulse of 0.2 ms) to the
ulnar nerve at the wrist. The size of MEPs was expressed
as a percentage of the supramaximal M wave amplitude
(Amplitude ratio). Moreover, to assess spinal motor excit-
ability, the mean amplitude of the F wave was measured
in the target muscle. ICI and ICF were studied using the
conditioning-test paradigm described by Kujirai et al. [38]
through a Bistim module (The Magstim Company) con-
nected to a Cambridge Electronic DesignMicro 1401interface (Cambridge, UK). The procedure consisted of
applying two magnetic stimuli in rapid succession through
two magnetic stimulators connected to each other. The
conditioning stimulus was applied at 80% of the subject’s
rMT, and the intensity of the test stimulus was set at
130% of the rMT. The ISIs tested were 1, 3, 5, 7, 10, and
15 ms. Ten trials for each ISI were recorded randomly
with an 8-second interval between each trial. The re-
sponses were expressed as the ratio of the MEP ampli-
tude produced by paired stimulation to that produced
by test stimulation alone. The use of a Bistim module
was limited to the paired-pulse TMS measurements only,
whereas all other investigations were performed using the
single-pulse technique. All measurements were conducted
while subjects were seated in a comfortable chair with
continuous electromyographic monitoring to ensure
either a constant level of electromyographic activity dur-
ing tonic contraction or complete relaxation at rest. Data
were collected on a computer and stored with software
ad hoc for off-line analysis [39]. All procedures described
above were performed in the same laboratory and situ-
ation, by the same operators for each subject at the
same time during the day (approximately 3–5 pm).
Statistical analysis
The non-parametric Kruskal-Wallis ANOVA test was
used for comparison of clinical, neuropsychological, and
neurophysiological variables obtained from patients and
controls (followed by the Mann–Whitney test for post-
hoc analysis for the comparison between pairs of groups),
and the χ2 test was used for categorical variables. The
Wilcoxon test for paired data sets was used for the com-
parison between hemispheres of patients and controls.
Nonparametric statistics were used because of the cat-
egorical nature of the neuropsychological testing results,
and the non-Gaussian distribution of the results of the
TMS studies. A p value lower than 0.05 was considered
statistically significant.
Results
The relevant demographic and clinical characteristics of
the two patient groups are summarized in Tables 2 and
3. MD were younger than VD patients and controls. The
depression rating was less severe in the VD group com-
pared with the MD group. As expected, hypertension
was more frequent in VD compared with MD patients,
whereas personal history of depressive symptoms was the
opposite, and scores at Stroop T were worse in patients
compared with controls. WML severity was mild in 4,
moderate in 5, and severe in 2 patients. Brain MRI of MD
patients and controls was unremarkable (Fazekas 0), and
the physical and mental state of controls was also unre-
markable. As shown in Table 4, there was a significant
increase in rMT in MD patients in the left hemisphere
Table 2 Demographic and neuropsychological characteristics of patients and controls
Variable VD MD Control Kruskal Wallis ANOVA
H(2.33) p-value
Age 67.72 ± 3.29 57.18 ± 7.12 67.36 ± 3.75 12.20 0.002*
Age at onset 62.27 ± 5.04 27.82 ± 7.32 – – –
Education 7.91 ± 5.75 12.18 ± 5.98 9.64 ± 5.08 3.25 0.197
MMSE 26.62 ± 1.58 27.53 ± 2.03 28.36 ± 1.85 5.49 0.064
ADL 5.82 ± 0.40 5.81 ± 0.6 6 ± 0 2.00 0.366
IADL 7.54 ± 1.21 7.36 ± 1.027 7.82 ± 0.4 1.39 0.498
HAM-D17 15.91 ± 7.23 20.27 ± 4.41 4.73 ± 2.41 23.02 0.00001*
SCID-I 2.00 ± 0.00 2.00 ± 0.00 – – –
StroopT 45.70 ± 17.88 34.09 ± 14.37 26.6 ± 11.29 6.82 0.0330*
StroopE 2.38 ± 2.71 1.36 ± 1.63 0.94 ± 1.14 1.98 0.370
FAB 15.24 ± 2.33 15.12 ± 1.61 16.5 ± 1.78 3.17 0.204
VD = vascular depression; MD =major depression; MMSE =Mini Mental State Examination; ADL = Activity of Daily Living; IADL = Instrumental Activity of Daily
Living; HAM-D17 = 17-items Hamilton Depression Rating Scale; SCID-I = Structured Clinical Interview for DSM-IV Axis I Disorders; Stroop T = Stroop Color-Word Test
interference score; Stroop E = Stroop Color-Word Test interference number of errors; FAB = Frontal Assessment Battery. Data are expressed as mean ± SD and were
analyzed using Kruskal-Wallis ANOVA. * = p < 0.05.
Concerto et al. BMC Psychiatry 2013, 13:300 Page 5 of 10
http://www.biomedcentral.com/1471-244X/13/300compared with the right (48.36 ± 9.64 vs. 45.00 ± 8.82;
p < 0.05). No significant differences were found between
the right and left hemispheres for the other measures
of cortico-spinal excitability in VD patients, except for
a trend toward an increase in ICF at the ISI of 15 ms
from the right hemisphere (VD 2.08 ± 0.7 vs. MD 1.78 ±
0.87 vs. Controls 1.52 ± 0.75, p = 0.153) (Figures 1 and 2).
No significant differences were found in rMT, central
motor conduction time, amplitude ratio, and mean ampli-
tude of the F wave between VD, MD, and controls. In MD
patients, the duration of the CSP from both hemispheres
was increased, which was significant from the left hemi-
sphere (MD 115.00 ± 32.39 vs. VD 72.18 ± 26.57 vs. Con-
trols 80.09 ± 19.19, p = 0.004), and there was a trend
towards significance from the right hemisphere (MD
111.82 ± 42.09 vs. VD 85.45 ± 45.13 vs. Controls 79.18 ±
21.51, p = 0.105) (Table 4).Table 3 Clinical characteristics of patients and controls
Variable VD MD
Gender (male/females) 6/5 5/6
Hypertension 9 (81.8%) 3 (27.3%)
Atrial fibrillation 1 (9.1%) 0 (0%)
Coronaropathy 1 (9.1%) 2 (18.2%)
Hypercholesterolemia 7 (63.6%) 5 (45.5%)
Diabetes 3 (27.3%) 3 (27.3%)
Familial History 4 (36.4%) 2 (18.2%)
Personal History 6 (54.5%) 11 (100%)
Smoking Habits 7 (63.6%) 4 (36.4%)
VD = vascular depression; MD = major depression. * = p < 0.05.Discussion
This is the first report comparing motor cortex excitability
between VD and MD patients. The main finding is the
observation of potentially distinctive neurophysiological
profiles elicited by TMS, adding support to the hy-
pothesis that late onset VD is a different syndrome with
respect to early onset recurrent MD. Despite the abun-
dant literature on TMS and depression, only one study
has been conducted in VD patients, where VD patients
were compared with patients with SVD patients and
controls [30]. The results of this study confirm previous
findings on VD, and are consistent with most TMS
reports investigating MD. An interhemispheric imbal-
ance in frontal cortical activities, as indexed by a higher
rMT, was observed in our MD patients and is con-
sistent with an overall hypoexcitability of the left hemi-
sphere [15-17].Control Chi-square p-value
6/5 0.243 0.886
7 (63.6%) 6.947 0.031*
0 (0%) 2.063 0.357
0 (0%) 2.200 0.333
4 (36.4%) 1.699 0.428
1 (9.1%) 1.451 0.484
4 (36.4%) 1.148 0.563
2 (18.2%) 15.135 0.001*
3 (27.3%) 3.226 0.199
Table 4 TMS parameters of the patient and the control groups obtained from both hemispheres
Variable VD MD Controls Kruskal Wallis ANOVA
H(2.33) p-value
Left rMT 46.00 ± 10.57 48.36 ± 9.64 45.18 ± 6.90 0.451 0.797
CSP 72.18 ± 26.57 115.00 ± 32.39 80.09 ± 19.20 11.182 0.0037*
MEP latency 20.82 ± 2.17 20.28 ± 0.66 20.57 ± 1.73 0.036 0.981
CMCT 6.22 ± 0.97 6.00 ± 1.06 6.19 ± 1.34 0.423 0.809
CMCTF 6.21 ± 0.92 5.33 ± 0.86 6.23 ± 1.28 4.536 0.103
A Ratio 0.40 ± 0.15 0.42 ± 0.13 0.35 ± 0.10 2.786 0.248
F Wave A 0.33 ± 0.50 0.28 ± 0.17 0.13 ± 0.05 3.622 0.163
Right rMT 44.00 ± 7.80 45.00 ± 8.82 44.91 ± 5.41 0.035 0.982
CSP 85.45 ± 45.13 111.82 ± 42.09 79.18 ± 21.51 4.503 0.105
MEP latency 20.47 ± 2.06 19.96 ± 1.09 19.71 ± 1.53 0.747 0.688
CMCT 5.82 ± 0.71 5.51 ± 1.05 5.46 ± 0.87 0.872 0.646
CMCTF 5.87 ± 0.76 4.89 ± 0.91 5.45 ± 1.21 5.375 0.068
A Ratio 0.52 ± 0.13 0.35 ± 0.16 0.46 ± 0.12 6.876 0.031*
F Wave A 0.31 ± 0.60 0.10 ± 0.07 0.10 ± 0.04 2.680 0.261
Variable Left Right Wilcoxon test
T p-value
VD rMT 46.00 ± 10.57 44.00 ± 7.80 11.50 0.192
CSP 72.19 ± 26.57 85.45 ± 45.13 23.00 0.373
MEP latency 20.82 ± 2.17 20.47 ± 2.06 19.50 0.230
CMCT 6.22 ± 0.97 5.82 ± 0.71 16.00 0.130
CMCTF 6.21 ± 0.92 5.87 ± 0.76 17.00 0.154
A Ratio 0.40 ± 0.15 0.52 ± 0.13 6.00 0.016*
F Wave A 0.33 ± 0.50 0.31 ± 0.60 21.00 0.507
MD rMT 48.36 ± 9.64 45.00 ± 8.82 1.00 0.017*
CSP 115.00 ± 32.39 111.82 ± 42.09 24.00 0.721
MEP latency 20.28 ± 0.66 19.96 ± 1.09 14.50 0.185
CMCT 6.00 ± 1.06 5.51 ± 1.05 12.50 0.126
CMCTF 5.33 ± 0.86 4.89 ± 0.91 13.00 0.139
A Ratio 0.42 ± 0.13 0.35 ± 0.16 5.00 0.248
F Wave A 0.28 ± 0.17 0.10 ± 0.07 3.00 0.012*
Control rMT 45.18 ± 6.90 44.91 ± 5.41 19.50 0.722
CSP 80.09 ± 19.20 79.18 ± 21.51 31.00 0.858
MEP latency 20.57 ± 1.73 19.71 ± 1.53 3.00 0.007*
CMCT 6.19 ± 1.34 5.46 ± 0.87 13.00 0.075
CMCTF 6.23 ± 1.28 5.45 ± 1.21 3.00 0.020*
A Ratio 0.35 ± 0.10 0.46 ± 0.12 10.00 0.040*
F Wave A 0.13 ± 0.05 0.10 ± 0.04 10.00 0.138
VD = vascular depression; MD =major depression; rMT = resting motor threshold (%); CSP = cortical silent period (ms); CMCT = central motor conduction time (ms);
CMCTF = central motor conduction time calculated with F-waves (ms); A ratio = amplitude ratio; F wave A = amplitude of F-waves (mV). Data are expressed as
mean ± SD. * = p < 0.05.
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Mann [40] described structural asymmetries in cortical
and subcortical brain regions crucial in the neuroana-
tomical model of mood disorders. More recently, it hasbeen reported that decreased relative left-frontal brain
electrical activity may be a trait-like marker of depres-
sion, suggesting that frontal asymmetry could also be
a shared factor predicting first depression onset [41].
Figure 1 MEP amplitudes at different ISIs from the 3 groups
with respect to the hemisphere. Data are expressed as mean ± SE.
(whiskers). VD= vascular depression; MD=major depression; C = Controls;
MEP =Motor Evoked Potential; ISI = Interstimulus Interval.
Figure 2 Curves of intracortical excitability obtained from both
hemispheres in each group.
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metry between the left and right prefrontal cortices by
examining differences in motor responses to TMS only.
Findings from previous studies conclude that both gluta-
matergic and GABAergic pathways may be defective in
the left hemisphere of patients with MD. The effect of
laterality has also been reported in patients with late-life
depression and MRI signal hyperintensities, but it is still
controversial as some reports found that left-sided WMLs
were significantly associated with older age of depres-
sion onset [42], whereas others did not find any lateral-
ity effect [43].
Although many, but not all, TMS studies in MD have
shown a significant reduction in the amount of both in-
hibitory (shortened CSP and decreased ICI) and facilita-
tory (reduced ICF) inputs regarding the left frontal cortex
compared with the contralateral hemisphere [17-19], we
were not able to find substantial differences. On the con-
trary, we observed a bilateral increase in CSP duration.
The reason for this dissociation remains unclear. Previous
studies have obtained conflicting results, probably due tothe heterogeneous methods employed, differences in clin-
ical presentation and severity as well as the medication
status. For example, Bajbouj et al. [17] and Lefaucheur
et al. [18] found reduced CSP and ICI in medication-
free and treated MD patients, respectively. Additionally,
Fitzgerald et al. [16] did not observe consistent differ-
ences in hemispheric activity in drug-resistant MD
patients, whereas Levinson et al. [19] demonstrated
significantly shortened CSP duration in all MD patient
groups and decreased ICI in the drug-resistant group
only. In contrast, one study observed an increased CSP
in MD patients compared with age-matched controls,
suggesting increased cortical inhibition [44]. In our study,
however, we cannot exclude the possibility of a drug-
induced effect on CSP duration, related to zolpidem
administration in many MD patients (but not in VD
group or controls), highlighting the role of specific sub-
types of GABA receptors in the control of inhibitory
neuronal loops within the M1 [45]. It is more difficult
to explain a drug effect on ICI since it has been shown
to be affected by benzodiazepine administration but
not zolpidem, and this is consistent with the different
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cortex at the level of GABA receptor subtypes [46].
Regarding the facilitatory component of intracortical
excitability, we observed a trend toward an increase in
ICF in VD patients, supporting previous results [30]. A
significant hyperfacilitation was found in patients with SVD
and clinical features of vascular cognitive impairment-no
dementia (VCI-ND) [47], although it was not observed at
follow-up [48], supporting the concept that specific TMS
measures of cortical excitability can be considered indices
of motor cortex plasticity [49]. SVD is indeed a potential
aetiology of both VD and VCI and the accumulation
of microvascular lesions constitutes a common neuro-
pathological platform for both cognitive decline and de-
pressive episodes in old age [6].
A growing body of evidence indicates that glutamate-
mediated compensatory plastic events might also occur
in MD [50]. In a recent paper, Spampinato et al. [34]
demonstrated that repetitive TMS (rTMS) improved per-
formance in a test evaluating frontal lobe abilities and
was able to restore inter-hemispheric asymmetry of the
ICF and rMT. These results suggested that the TMS
changes observed before treatment might be the expression
of disruption of glutamatergic receptor plasticity-related
processes, and that this neurophysiological behaviour might
correlate with executive functions.
Taken together, the data presented here may help to fur-
ther understanding of the pathogenetic differences under-
lying the clinical spectrum of depressive disorders. However,
relating the distinctive electrophysiological profile between
VD and MD patients to what is clinically observed is chal-
lenging. Currently, it is difficult to relate the subtle TMS
changes with the clinical picture of psychomotor retard-
ation, persistent symptoms, and prominent disability seen
in patients with VD. It has been proposed that vascular
damage to the reciprocal connections between the pre-
frontal cortex, basal ganglia, and cerebellum may affect
the presentation and the course of late-life VD, although
the atrophy of frontal grey matter due to deafferentation
could also contribute [10]. Finally, although not statisti-
cally significant, we did observe some trends in this study
that may be of interest in future studies. For example, the
MMSE scores obtained in patients with VD were lower
compared with the MD group and controls (p = 0.064),
although all values were within normal limits. This could
be related to poorer educational level in the VD group,
and the clinical presentation and vascular burden. The
significance of other trend-level differences, such as for
the CMCT from the right hemisphere among the three
groups (p = 0.068), and for the CMCT between the left
and right side in controls (p = 0.075), is unclear although
they may not have a significant clinical relevance, and are
likely arising from procedural variability or related to the
small samples size in this study.The findings of this study must be viewed in light of
some important limitations. The main limitation is the
relatively small number of patients, although they were
matched with controls without WMLs that are strikingly
prevalent among the elderly. Secondly, given the well-
known effect of neuroactive drugs on TMS measures of
cortical excitability, we cannot exclude a drug-induced
effect on the results. Nevertheless, taking into account
these possible interactions, we selected patients assum-
ing psychotropic drugs minimally affected cortico-spinal
excitability [51-54], and who were not withdrawn from
psychotropic drugs that were unchanged and unmodi-
fied in terms of the daily dosage throughout the course
of the study. Moreover, medications taken by patients
with MD belonged to relatively few classes whose mem-
bers all share a common mode of action, thus providing
more consistent results on the TMS excitability measure
[53]. Furthermore, the within- and between-subject vari-
ability was minimized, as stated above. The medicaments
taken by the VD group for treatment of vascular risk
factors (anti-thrombosis agents, anti-hypertensive drugs,
statins, oral anti-diabetes therapy) have no supporting data
with respect to the possible influence on motor excitability
parameters. Motor cortex excitability is unaffected in
insulin-dependent diabetic patients when compared with
normo- and hyperglycaemic subjects [55], except for a
single study reporting a lack of facilitation at an ISI of
30 ms in diabetic patients compared with controls (ISI
not explored in the present paper) [56]. Thirdly, transfer
TMS findings obtained from stimulation of the M1 to
other brain regions, such as those involved in the patho-
physiology of depressive disorders, is challenging, and
requires further investigation. Finally, although this sam-
ple of drug-resistant depressed patients is not likely to be
representative of the whole population of patients with
recurrent MD, it is homogeneous in the terms of the
clinical features and neuropsychological profile.
Conclusions
The current study showed distinctive patterns of motor
cortex excitability between late-onset depression with SVD
and early-onset recurrent MD, providing a potential TMS
model of the different processes underlying them. These
results support the “Vascular depression hypothesis” at
the neurophysiological level and confirm inter-hemispheric
asymmetry to TMS in MD. Further research and compari-
son studies with homogeneous groups of patients and
other methodologies are needed to confirm the present
findings, as well as their modifications over time and
clinical correlates.
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